TriangleTalquetamab (NCT06827860)
Talquetamab trial for Multiple Myeloma in Relapse (NCT06827860). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults aged 70+ with relapsed or refractory multiple myeloma after at least two treatment lines, including a proteasome inhibitor and an immunomodulatory drug.
The idea: talquetamab links T cells to GPRC5D on myeloma cells. Injections under the skin start with step-up doses, then every other week. Daratumumab may be added for inadequate response or progression, but only without prior anti-CD38 resistance. Researchers measure myeloma responses and safety.
This phase 2 study plans 23 patients. Larysa Sanchez leads it at Mount Sinai in New York, the single recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.